|
| 36126289 | Antimicrobial Efficacy of Continuous Low-Irradiance Phototherapy Against Multidrug-Resistant Organisms. | Photobiomodul Photomed Laser Surg | 2022 |
| 33858243 | A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis. | Innate Immun | 2021 |
| 33672437 | Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock. | Int J Mol Sci | 2021 |
| 32198163 | Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. | mBio | 2020 |
| 31733673 | Biomarkers of Infection and Sepsis. | Crit Care Clin | 2020 |
| 33045189 | Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19. | Lancet | 2020 |
| 32690640 | Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia. | Antimicrob Agents Chemother | 2020 |
| 32212525 | Activating Immunity to Fight a Foe - A New Path. | N Engl J Med | 2020 |
| 32471831 | Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure". | mBio | 2020 |
| 31104069 | Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. | JAMA | 2019 |
| 31585759 | Should we continue to test soluble thrombomodulin, or other systemic anticoagulants, as a life-saving therapy for sepsis-induced coagulopathy? | Anaesth Crit Care Pain Med | 2019 |
| 31577035 | Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. | JAMA | 2019 |
| 31367740 | An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic. | Clin Infect Dis | 2019 |
| 30814582 | Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis. | Sci Rep | 2019 |
| 30828456 | Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort. | J Intensive Care | 2019 |
| 31028466 | Inter-α-inhibitor Ameliorates Endothelial Inflammation in Sepsis. | Lung | 2019 |
| 31104070 | Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. | JAMA | 2019 |
| 28991823 | Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration. | Crit Care Med | 2018 |
| 30126574 | Antibiotic Stewardship: Strategies to Minimize Antibiotic Resistance While Maximizing Antibiotic Effectiveness. | Med Clin North Am | 2018 |
| 29875013 | Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis. | Crit Care | 2018 |
| 30420852 | Coinfection With Influenza A Virus and <i>Klebsiella oxytoca</i>: An Underrecognized Impact on Host Resistance and Tolerance to Pulmonary Infections. | Front Immunol | 2018 |
| 30409091 | Whatever happened to the Shwartzman phenomenon? | Innate Immun | 2018 |
| 29581049 | Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. | Clin Microbiol Infect | 2018 |
| 29388815 | Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial. | Ann Am Thorac Soc | 2018 |
| 29632995 | Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). | Intensive Care Med | 2018 |
| 29624409 | Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. | Am J Respir Crit Care Med | 2018 |
| 28069650 | Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia. | Antimicrob Agents Chemother | 2017 |
| 28194511 | Should all septic patients be given systemic anticoagulation? No. | Intensive Care Med | 2017 |
| 28130686 | Sepsis: frontiers in supportive care, organisation and research. | Intensive Care Med | 2017 |
| 28159171 | Severe Pneumonia Caused by Legionella pneumophila: Differential Diagnosis and Therapeutic Considerations. | Infect Dis Clin North Am | 2017 |
| 28396715 | Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy. | World J Stem Cells | 2017 |
| 29169402 | Age, exercise, and the outcome of sepsis. | Crit Care | 2017 |
| 28910137 | The Role of S1PR3 in Protection from Bacterial Sepsis. | Am J Respir Crit Care Med | 2017 |
| 27984280 | Source Control in Sepsis Urgent or Not So Fast? | Crit Care Med | 2017 |
| 26974318 | PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. | Shock | 2016 |
| 28117397 | Sepsis and septic shock. | Nat Rev Dis Primers | 2016 |
| 26584195 | Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. | Crit Care Med | 2016 |
| 27978847 | Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance. | Crit Care | 2016 |
| 27713886 | The role of genetics and antibodies in sepsis. | Ann Transl Med | 2016 |
| 26863125 | THE EPITHELIUM AS A TARGET IN SEPSIS. | Shock | 2016 |
| 26992066 | Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials. | Crit Care Med | 2016 |
| 26886007 | Isolating Influenza RNA from Clinical Samples Using Microfluidic Oil-Water Interfaces. | PLoS One | 2016 |
| 27015977 | A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. | J Biotechnol | 2016 |
| 26908575 | Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?". | mBio | 2016 |
| 26903338 | The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). | JAMA | 2016 |
| 26975243 | Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story. | JAMA | 2016 |
| 25305323 | CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis. | J Infect Dis | 2015 |
| 26252194 | The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. | Am J Respir Crit Care Med | 2015 |
| 26426779 | Is genomic medicine finally coming of age for the diagnosis of pneumonia? | Am J Respir Crit Care Med | 2015 |
| 26106080 | Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. | mBio | 2015 |